Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Screening People Aged 50 for Early Risk of Type 2 Diabetes and Heart Disease

Tests a screening program for diabetes and heart disease risk in 50-year-olds.

Plain-language title generated from the registry record
Registry title: "Screening for Change: Early Risk Detection and Integrated Prevention for Diabetes and Cardiovascular Diseases in the Marche Region"

Key facts

Where
Ascoli Piceno and San Benedetto del Tronto, ItalySee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 50 years old?

Source: NCT07344701, who can take part

Where in Italy

  • Prevention Department of Ascoli Piceno ProvinceAscoli Piceno, ItalyTaking people
  • Prevention Department of Ascoli Piceno ProvinceSan Benedetto del Tronto, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Marche Region Regional Health Agency
Trial code
NCT07344701
Record updated
17 August 2026
Original description
This study aims to test the feasibility of a new systematic screening program to allow the early detection of individuals aged 50 years at risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) in the resident in the province of Ascoli Piceno and without previous diagnosis, using the CUORE and FINDRISDC tools developed in the Project.Read full original descriptionShow less

Early Risk Detection of Type 2 Diabetes and Cardiovascular Diseases: an Italian Cohort Study

This study aims to test the feasibility of a new systematic screening program to allow the early detection of individuals aged 50 years at risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) in the resident in the province of Ascoli Piceno and without previous diagnosis, using the CUORE and FINDRISDC tools developed in the Project.

The intervention will be conducted at the premises of the Prevention Department in Ascoli Piceno and San Benedetto del Tronto, within the Local Health Authority of Ascoli Piceno (Marche Region, Italy), throughout 2026.

Eligible individuals will be invited, based on recruitment criteria, to the screening via a letter containing study information and participation instructions. Those willing to participate will book the appointment to undergo the screening in one of the two premises of the Prevention Department involved in the study (namely, San Benedetto del Tronto and Ascoli Piceno), through the regional reservation system (CUP). On the scheduled date, participants will visit the Prevention Department, where healthcare professionals (HCPs) will explain the study, obtain the informed consent, and collect data related to the CUORE and/or FINDRISC questionnaires, as well as sociodemographic information. The calculated scores will determine the 10-year risks of T2DM and major CVD events. Based on these risks, participants will be provided with tailored suggested pathways. A summary letter outlining these pathways will be delivered, and, in case of consent, results will be added to the participants' Electronic Health Record. Follow-up calls will be scheduled at 3 (T1) and 6 (T2) months to assess adherence to the suggested pathway (e.g., visit the General Practitioner (GP), lifestyle counselling) through a phone call.

Inclusion: Citizens resident in Ascoli Piceno province; People turning 50 in 2026; Capacity to consent; Fulfilling and signing the informed consent related to the participation to the study.

Exclusion: a concomitant diagnosis of DM and a previous CVD major event (one or more between Myocardial infarction, Haemorrhagic and/or ischaemic stroke, Revascularization interventions, as percutaneous coronary intervention/coronary artery bypass graft); Failure to meet the inclusion criteria; Lack of written informed consent.

ClinicalTrials.gov NCT07344701